Aim: To investigate determinants of change in glycated haemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM) at 6 months after initiating uninterrupted second-line glucoselowering therapies.
| INTRODUCTION
Type 2 diabetes mellitus (T2DM), a chronic and increasingly prevalent disease, poses a significant clinical and economic burden worldwide. 1 The pathophysiology of T2DM is characterized by progressive decline in β-cell function, with a subsequent reduction in glycaemic control.
Given evidence for a causal link between dysglycaemia and the development of microvascular and macrovascular complications, controlling blood glucose levels is a major goal of therapy in patients with T2DM. [2] [3] [4] Current clinical guidelines recommend the use of metformin (MET), in conjunction with lifestyle changes, as first-line glucoselowering therapy in patients with no contraindications who can tolerate this therapy. [5] [6] [7] [8] When MET monotherapy fails to control Diabetes (EASD) recommends treatment intensification if glycaemic control is not achieved after 3 months of initial therapy. 6 In clinical practice, several second-and subsequent-line therapies are used to treat patients with T2DM, because of a lack of clear consensus on the optimal treatment regimen for the management of hyperglycaemia, as well as inter-patient differences in the efficacy and safety profiles of different therapies. 6, 9 The global DISCOVER study programme (NCT02322762 and NCT02226822) is designed to address this knowledge gap. 10 DISCOVER comprises 2 prospective observational studies of patients with T2DM who initiated secondline glucose-lowering therapy (defined as adding a glucose-lowering drug or switching between therapies) after failure of first-line oral treatment (mono-, dual or triple therapy). The studies aim to describe disease management patterns and treatment outcomes in patients with T2DM worldwide, and over 16 000 patients in 38 countries across 6 continents have been enrolled. As part of the DISCOVER study programme, a retrospective analysis was conducted, using data from existing electronic medical record (EMR) databases in Canada,
France, Germany and the UK.
This paper reports on an analysis using data from Germany and the UK. The aims of the present study are: (1) to describe the changes in HbA1c in patients with T2DM 6 months after initiating a second-line therapy; and (2) to assess patient characteristics that influence changes in HbA1c after 6 months of second-line treatment.
2 | METHODS
| Study design and data source
In this longitudinal cohort study, EMR patient-level data from 2 countries were extracted from 2 databases: the IMS Disease Analyzer in Germany compiles drug prescriptions, diagnoses and basic medical and demographic data from the computer systems of a representative sample of primary care physicians and internal medicine practices in
Germany
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; The Health Improvement Network (THIN) contains healthcare information from patients registered with participating primary healthcare practices in the UK. 12 Studies have shown THIN to be representative of the UK population in terms of patient demographics and the prevalence of major conditions. 13, 14 No ethical approval is required for studies based on anonymized databases in Germany. Studies using THIN have been approved by a nationally accredited ethics committee 12 and specific approval was obtained for this study from the relevant Scientific Review Committee before study initiation (reference number: 14THIN052).
| Study population
Inclusion and exclusion criteria were based on key criteria used in the prospective DISCOVER studies. These linear regression models were also used to assess the had remained on MET monotherapy for ≥5 years.
| Type 2 diabetes mellitus treatments
For most patients, second-line treatments initiated at baseline com- Table 1) .
Second-line treatment choices differed between countries. Insulin was more commonly chosen in Germany (4.8%) than in the UK (0.3%) and second-line monotherapies were more common in Germany (46.3%) than in the UK (12.1%). While MET + SU was the most common second-line treatment choice in the UK (56.8%), it was rarely chosen in Germany (4.4%), where DPP-4i treatment predominated (data not shown).
| Changes in HbA1c at 6 months
The mean (SD) change in HbA1c at 6 months after initiation of second-line therapy was −1.27% (1.8) ( Table 1) (Table 2 ); values were highest in patients whose second-line treatment was insulin (9.48%) or MET + SU (9.22%), and lowest in those who switched to DPP-4i monotherapy (7.72%). After 6 months of second-line treatment, HbA1c decreased in all treatment groups and there were small differences in the magnitude of this decrease between groups (Table 2 and Figure S1 ). The combination of MET + SU was associated with the largest decrease in HbA1c (1.09%); SU reduced HbA1c to a greater extent than did DPP-4i, both when used alone (difference of 0.08%, P = .023) and in combination with MET (difference of 0.07%, P < .001). Combining MET with SU or DPP-4i
reduced HbA1c more than either monotherapy alone (SU alone: difference of 0.06%, P = .049; DPP-4i alone: difference of 0.12%, P < .001; overall difference from monotherapy: 0.09%, P < .001).
Data analysed separately for Germany and the UK are presented in Tables S1a and S1b (Appendix S1); data showing the proportions of patients achieving HbA1c <7.0% after 6 months, according to second-line treatment and baseline HbA1c category, are presented in Tables S2a and S2b (Appendix S1) . Additionally, a sensitivity analysis We next examined whether the relative treatment effects were dependent on baseline HbA1c by splitting the overall cohort into patients with baseline HbA1c <9.0% (n = 6923 [67.5%]) and ≥9.0%
(n = 3333 [32.5%]) ( Table 2 ). The results of this subgroup analysis were generally consistent with findings from the overall cohort. However, there were several differences; while mean baseline-adjusted HbA1c reduction was smallest with DPP-4i monotherapy in the main analysis, this was not the case in the subgroup of patients with HbA1c ≥9.0%. It is important to note that the number of patients with HbA1c ≥9.0% who received DPP-4i monotherapy was small (n = 150 vs 881 in the <9.0% group).
In patients with baseline HbA1c ≥9.0%, the mean baselineadjusted reduction in HbA1c was slightly greater in patients who initiated insulin as second-line treatment (3.05%), compared with the other treatment groups (P = .036 vs all other treatment groups combined). However, the number of patients in this insulin-treated subgroup was small (n = 86). Table 3 ).
| Time between diagnosis of type 2 diabetes mellitus and initiation of second-line therapy
Mean HbA1c at baseline was higher in patients starting second-line treatment during the 6 months following diagnosis (9.88%) than in those starting treatment beyond this time point (8.70% and 8.55% at 6 months to <1 year and at ≥1 year, respectively; Table 3 ). The mean baseline-adjusted 6-month change in HbA1c was significantly greater in patients who initiated treatment during the 6 months following T2DM diagnosis, than in those who initiated treatment ≥6 months after T2DM diagnosis (−1.36% vs −1.03%; P < .001).
| Age
Patients who switched to another monotherapy as second-line treatment tended to be older than those receiving second-line combination therapies (mean age of patients initiating non-MET monotherapy (−1.02%) than in patients aged ≥70 years (−1.13%; P < .001) ( Table 3 ). 
| Body mass index
| Sex
In patients receiving an SU or DPP-4i as monotherapy or in combination with MET, women were more likely than men to switch to another Table 3 ).
| Multivariable regression analysis
When simultaneously modelling the effects of all previously examined variables on 6-month change in HbA1c, we found that the following were significantly associated with greater baseline-adjusted 6-month reductions in HbA1c: residence in Germany (vs the UK); <6 months between T2DM diagnosis and second-line treatment initiation; older age; lower BMI and male sex (vs female) ( Table 4 ). HbA1c reductions were higher with MET + SU compared with other second-line treatment options, but the differences between groups were small. Thus, overall, the findings from this multivariate regression analysis were consistent with the results of univariate anaysis.
4 | DISCUSSION
| Overview of study findings
The aim of this study was to elucidate determinants of change in 
| Treatment patterns in patients initiating second-line therapy
A key finding from this study was that most (89%) patients had inadequate glycaemic control (baseline HbA1c ≥7.0%) and almost one-third of patients had baseline HbA1c ≥9.0%. This is suggestive of a delay in treatment intensification, as has been reported in several real-world studies in the UK and elsewhere. received early intensive glucose-lowering therapy experienced a continued reduction in microvascular risks, as well as emergent risk reductions for cardiovascular events, compared with patients who received conventional therapy.
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A second important finding was that, despite guideline recommendations to add additional glucose-lowering agents to MET as second-line therapy, almost 25% of patients in the study cohort discontinued MET and switched to another monotherapy or insulin (either as add-on or as a single agent). However, it is important to acknowledge that an early change in therapy is often attributable to poor medication tolerability, rather than a lack of glycaemic control. MET is associated with gastrointestinal side effects in approximately 25% of patients and is also contraindicated in patients with renal impairment. 20, 21 Furthermore, it is noteworthy that the 11% of patients in the present analysis with HbA1c <7.0% are more likely than others to have switched therapies because of poor MET tolerance. Unfortunately, data on patients' reasons for switching from MET therapy were not documented in the databases used in this study.
Most patients in the study cohort (71.6%) initiated add-on therapy with an additional glucose-lowering agent, consistent with guideline recommendations. [5] [6] [7] [8] The most commonly prescribed add-on therapies were SUs and DPP-4is. Interestingly, while MET + SU was the most popular choice of second-line treatment in the UK (56.8%), it was rarely chosen in Germany 
| Changes in 6-month HbA1c with second-line diabetes treatments
After 6 months of second-line treatment, HbA1c decreased in all treatment groups and there was a non-linear relationship between baseline HbA1c and 6-month HbA1c change. There were some small differences between treatment groups, with combination therapies associated with larger HbA1c reductions than monotherapies, and
SUs associated with slightly greater HbA1c reductions than DPP-4is.
However, these findings should be considered carefully, given that this was a descriptive study and, therefore, not designed to test hypotheses or to formally compare the effectiveness of treatments.
Therefore, it is our view that the choice of second-line treatment had only a modest impact on 6-month baseline-adjusted HbA1c reductions, even after controlling for covariates in a multivariable analysis.
Moreover, these findings were broadly consistent across all baseline HbA1c values. These real-world findings were consistent with a recent meta-analysis, in which all investigated drug classes lowered HbA1c to a similar extent when combined with MET, 26 as well as with findings from a primary care database study in Germany. 27 Given the similar efficacy of all second-line treatments, their associated side effects (eg, risks of weight gain, hypoglycaemia) and additional benefits (eg, weight reduction, blood pressure reduction) 6, 9 may be the most important considerations when selecting secondline treatment options for patients with T2DM.
| Additional determinants of change in HbA1c following initiation of second-line glucose-lowering therapies
As seen previously, there was a positive relationship between baseline HbA1c and the magnitude of 6-month HbA1c reductions. 28 Our multivariable analysis revealed 5 additional patient characteristics that affected baseline-adjusted 6-month HbA1c reductions following initiation of second-line glucose-lowering therapy. These included country, age and sex, as well as the "modifiable" variables: time since T2DM diagnosis and BMI. While the magnitude of the effects of country, BMI and sex were small and, therefore, probably insignificant from a clinical perspective, it is worth noting that small differences may have a cumulative effect when considered from a public health perspective. For example, the proportion of patients achieving HbA1c <7.0% after 6 months of continuous second-line treatment was higher in Germany than in the UK (46.9% vs 34.7%), an effect probably attributable to the lower mean baseline HbA1c and the slightly higher baseline-adjusted reduction in HbA1c in Germany compared with that in the UK (baseline HbA1c:
7.91% vs 9.02%; baseline-adjusted HbA1c reduction: 1.11% vs 1.04%).
Thus, it may be pertinent for clinicians to consider additional patient characteristics, particularly age and time since T2DM diagnosis, when making treatment decisions, in accordance with recommendations from a recent joint statement from the ADA and the EASD. Limitations of the present study include the fact that patient medical records show prescriptions rather than medication use, so analyses assume patient adherence to study medication. 29, 30 Additionally, the reasons for changing treatment or initiating a particular second-line therapy are not routinely captured in EMRs. Patients who switch therapy might be more likely to do so as a consequence of adverse events than of poor glycaemic control; the opposite may be true of patients who initiate add-on therapy to MET. EMR studies depend on recording of patient data by phycisians, which presents the possibility of some information being omitted; however, the frequency of this is expected to be low.
In this analysis, HbA1c data were not always available for the exact time points of interest, an issue that necessitated the use of time windows, and which may have impacted the precision of the analysis. There was also inconsistency in the accuracy and completeness of the variables of interest, and no data were included on prescription of diet or exercise or on the socio-economic status of patients. Furthermore, the present analysis does not include data from patients taking sodium-glucose linked transporter 2 inhibitors, an important new class of glucose-lowering drugs, because these medicines were not approved by the European Medicines
Agency at the start of the study. There are also no data on GLP-1RAs.
| Conclusions
Key findings from this study were, first, that second-line glucoselowering therapies are frequently initiated far later and at higher HbA1c levels than those recommended by guidelines. Second, almost one-quarter of patients in the study discontinued MET therapy, which is more than expected if guideline recommendations were applied. While the 6-month change in HbA1c did not differ much according to choice of second-line therapy, there was a non-linear relationship between baseline HbA1c and 6-month HbA1c changes.
Moreover, certain additional patient characteristics, including time since T2DM diagnosis and age, merit consideration when making treatment decisions. These data will complement future results from the prospective DISCOVER studies.
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